1019387-83-7

Basic information

• Product Name: 2-(Isopropylamino)-5-nitrobenzenecarboxylic acid
• Synonyms: 2-(Isopropylamino)-5-nitrobenzenecarboxylic acid
• CAS NO: 1019387-83-7
• Molecular Formula: C10H12N2O4
• Molecular Weight: 224.21328
• Mol File: 1019387-83-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(Isopropylamino)-5-nitrobenzenecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Isopropylamino)-5-nitrobenzenecarboxylic acid(1019387-83-7)
• EPA Substance Registry System: 2-(Isopropylamino)-5-nitrobenzenecarboxylic acid(1019387-83-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1019387-83-7(Hazardous Substances Data)

Upstream product

• 7304-32-7 2-fluoro-5-nitrobenzoic acid 
• 2965-22-2 methyl 2-fluoro-5-nitro-benzoate 
• 1221791-75-8 methyl 2-(isopropylamino)-5-nitrobenzoate 
• 474521-55-6 methyl 5-nitro-2-{[(trifluoromethyl)sulfonyl]oxy}benzoate 
• 17302-46-4 methyl 2-hydroxy-5-nitrobenzoate 

Relevant articles and documents

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors

Regulation of glycine transporter 1 (GlyT1) activity is a currently investigated strategy in drug discovery for schizophrenia. This study developed a series of new 4-benzoylpiperidine derivatives as GlyT1 inhibitors by bioisosteric replacement and mimicking of the pyridine ring of RG1678. Among the 4-benzoylpiperidine derivatives, 23q showed an IC50 of 30 nM. Preliminary optimization of the blood-brain barrier penetration led to the discovery of 3-(piperidin-4-yl)benzo[d]isoxazole derivatives. Both series showed good selectivity over GlyT2, D1, D2, D3, 5-HT1A and 5-HT2A receptors. Moreover, behavioral testing showed 23q (40 mg kg-1, intragastric) can inhibit the hyperlocomotion induced by acute treatment of phencyclidine, and improve the impaired negative and cognitive symptoms in chronic phencyclidine-induced C57BL/6J mice. An interesting finding showed that 3-(piperidin-4-yl)benzo[d]isoxazole was a privileged scaffold of atypical antipsychotic agents but exhibited high selectivity and potency as a GlyT1 inhibitor.